Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 412Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 83Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 55Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Carcinoma, Non-Small-Cell Lung 45Neoplasm Metastasis 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Prostatic Neoplasms 29Vaginal Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Small Cell Lung Carcinoma 22Urinary Bladder Neoplasms 21

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Mucinous Adenocarcinoma × Gynecologic × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡